Delivery Order SPE2DB20D3101-SPE2DB23FRWM7

Award Date 9/5/23
Potential Completion Date 9/6/23
Potential Value $4.1K
Ultimate Awardee
Cencora, Inc.
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,195.08 firm-fixed-price delivery order is for the supply of Cathflo Activase 2 mg vials, a specialty medication used for certain medical treatments. The award is part of a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support Medical....
This federal contract award is between the U.S. Defense Logistics Agency (DLA) Troop Support Medical and Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, valued at $9,039.44, is a delivery order under an Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA. The IDC, worth up to $999,999,999.00, serves as the primary vehicle for Amerisourcebergen to supply a comprehensive range of...
This federal contract award is for the delivery of Cathflo Activase 2 mg vials to the Defense Logistics Agency (DLA). The $9,044.45 Firm Fixed Price delivery order was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract has an ultimate completion date of November 13, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which provides a...
This federal contract award, valued at $2,141.80, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of CATHFLO ACTIVASE 2 MG VIALS, a critical medical product, with a performance period through October 2024. The award is a delivery order under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that Amerisourcebergen holds with the DLA Troop Support...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $10,427.39 Firm Fixed Price Delivery Order is for the supply of CATHFLO ACTIVASE 2 MG VIALS, a critical medical product, with a period of performance through December 17, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $26,545.12 firm fixed-price delivery order is for the supply of CATHFLO ACTIVASE 2 MG VIALS, a critical pharmaceutical product. This contract award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 between Amerisourcebergen and the DLA Troop Support Medical, which serves as a...
This federal contract award is for the delivery of Cathflo Activase 2 mg vials to the Defense Logistics Agency (DLA). The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has a ceiling value of $19,148.16 and is a firm fixed-price delivery order that runs through June 23, 2022. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which holds a significant $999,999,999 Indefinite...
This federal contract award, valued at $21,655.47, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order for the supply of CATHFLO ACTIVASE 2 MG VIALS, a critical medical product, with an ultimate completion date of October 29, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999...
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $10,188.23 firm fixed-price delivery order is for the supply of CATHFLO ACTIVASE 2 MG VIALS, a medical product. This contract award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, which serves as a primary vehicle...
This federal contract award is a delivery order issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,778.51 firm fixed-price contract is for the procurement of CATHFLO ACTIVASE 2 MG VIALS, a medical product, with a period of performance through February 19, 2025. This contract is not designated with a set-aside requirement, indicating open competition. AmerisourceBergen holds a significant...
  • SPE2DB20D3101
    Indefinite Delivery Contract
  • SPE2DB20D3101-SPE2DB23FRWM7
    Delivery Order

This federal contract award, valued at $4,085.60, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Cathflo Activase 2 mg vials, a critical medication. This award is a delivery order under Amerisourcebergen's larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. The IDC enables the DLA to efficiently procure a comprehensive range of pharmaceutical products and medical supplies, including specialty medications, brand-name and generic drugs, vaccines, syringes, and other essential medical commodities, to support military healthcare programs globally. This specific delivery order does not have a set-aside designation, indicating it was awarded through full and open competition.

Generated 2/27/25, 12:34 PM